Your browser doesn't support javascript.
loading
Development of a novel screening assay for inhibitors targeting HIF-1alpha and P300 interaction / 药学学报
Acta Pharmaceutica Sinica ; (12): 849-53, 2014.
Article Dans Chinois | WPRIM | ID: wpr-448662
ABSTRACT
Hypoxia is a general characteristic of most solid malignancies and intimately related to cancer progression. Homeostatic response to hypoxia is primarily mediated by hypoxia inducible factor-1alpha (HIF-1alpha) that elicits transcriptional activity through recruitment P300 coactivator. Targeting the interaction of HIF- alpha and P300 would thus constitute a novel approach for cancer treatment by suppressing tumor angiogenesis and metastasis. Here, a screening assay was developed for inhibitors targeting the interaction between HIF-1alpha and P300. The nucleotide sequence of human HIF-1alpha and P300 were cloned into pBIND and pACT vectors, named pBIND-HIF1alpha and pACT-P300. The interaction of HIF-1alpha and P300 was identified in HEK293 cell using mammalian two-hybrid system. And compound chetomin decreased their interaction in this mammalian two-hybrid system. We further verified HIF-1 inhibition effect of chetomin in U251-HRE cells. Therefore, we established a screening assay combined HIF-1alpha and P300 mammalian two-hybrid system and U251-HRE reporter assay for HIF-1 selective inhibitors.
Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Etude diagnostique / Étude pronostique / Étude de dépistage langue: Chinois Texte intégral: Acta Pharmaceutica Sinica Année: 2014 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Etude diagnostique / Étude pronostique / Étude de dépistage langue: Chinois Texte intégral: Acta Pharmaceutica Sinica Année: 2014 Type: Article